Related Experiment Video

Updated: Jun 16, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

The somatostatin receptor subtype 5 in neuroendocrine tumours

Joost van der Hoek1, Steven W J Lamberts, Leo J Hofland

  • 1Department of Internal Medicine, Division of Endocrinology, Room Ee530b, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. l.hofland@erasmusmc.nl

Expert Opinion on Investigational Drugs
|February 16, 2010
PubMed
Abstract

Insights

Novel somatostatin (SRIF) analogues targeting the SRIF receptor subtype 5 (sst5) show potential for treating neuroendocrine diseases like Cushing's disease and acromegaly. Further research is needed to establish sst5's role in gastroenteropancreatic neuroendocrine tumors.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Intensified research into somatostatin (SRIF) receptor subtype 5 (sst5) physiology and targeted analogues.
  • Focus on broadening therapeutic opportunities for neuroendocrine diseases.

Purpose of the Study:

  • Review recent insights into sst5 receptor physiology.
  • Explore novel sst5-targeted treatment options for pituitary adenomas and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Main Methods:

  • Literature review focusing on translational research and clinical trial data.
  • Analysis of pathophysiological data related to sst5 receptor function.

Main Results:

  • Translational research indicates potential of novel sst5-targeted SRIF analogues for Cushing's disease and acromegaly.
  • The role of sst5 targeting in GEP-NETs requires further investigation.

Conclusions:

  • Sst5 may modulate sst2 receptor activity and appears less critical than sst2 for pancreatic insulin secretion.
  • Absence of sst5 in corticotroph adenomas may correlate with Cushing's disease aggressiveness.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: